NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter ACCESSWIRE First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April FORT MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the ' Company' ), a leading provider of cancer-focused genetics testing services, today announced its first-quarter results for the period ended March 31, 2021. Mark W. Mallon, the Company's CEO said 'I couldn't be more excited to be joining NeoGenomics at such a pivotal time in the Company's history. Trends in the business are strong and we are positioned well to take market share as we emerge from the pandemic. Today's announced acquisition of Inivata along with the completion of the acquisition of Trapelo Health in April are significant milestones on our journey to become the world's leading cancer testing and information company and we expect both to accelerate NeoGenomics' long term growth rate.'